| Code | CSB-RA004931MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to otelixizumab, targeting CD3E (CD3 epsilon), a critical component of the T-cell receptor complex. CD3E forms heterodimers with CD3 delta and CD3 gamma chains and is essential for T-cell receptor assembly, surface expression, and signal transduction. This transmembrane protein plays a fundamental role in T-cell activation, development, and immune responses. Dysregulation of CD3E-mediated signaling is implicated in various autoimmune disorders, including type 1 diabetes, rheumatoid arthritis, and transplant rejection, making it a valuable therapeutic target for immune modulation.
Otelixizumab is a non-FcR-binding humanized anti-CD3 monoclonal antibody that has been investigated in clinical trials for type 1 diabetes and other autoimmune conditions. By binding to CD3E, it modulates T-cell function without depleting T-cell populations, offering a mechanism for inducing immune tolerance. This biosimilar antibody serves as a valuable research tool for investigating T-cell biology, autoimmune disease mechanisms, and immunotherapeutic strategies in preclinical studies.
There are currently no reviews for this product.